Clinical trial
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
NCT00476476 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00476476 |
|---|---|
| Title | Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar |
| Official title | A Phase II Trial of Tarceva (Erlotinib) in Women With Squamous Cell Carcinoma of the Vulvar |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Genentech, Inc. Industry Beth Israel Deaconess Medical Center Brigham and Women's Hospital Women and Infants Hospital of Rhode Island |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Squamous Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 41 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2012 |
| Completion | Oct 1, 2012 |
| First posted | May 22, 2007 |
| Last update posted | May 7, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: